TQA3038 / Sino Biopharm - LARVOL DELTA

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE SIRNA TQA3038 IN HEALTHY CHINESE VOLUNTEERS (AASLD 2024) - P1 | "Single dose of up to 800mg TQA3038 was safe and well tolerated in healthy volunteers. Plasma pharmacokinetic variables were well defined. These data are supportive to continue development in patients with chronic HBV infection."

Clinical • PK/PD data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Respiratory Diseases

A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B (clinicaltrials.gov) - P1/2 | N=162 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation